PMID- 33720093
OWN - NLM
STAT- MEDLINE
DCOM- 20210709
LR  - 20221219
IS  - 1536-4801 (Electronic)
IS  - 0277-2116 (Linking)
VI  - 72
IP  - 5
DP  - 2021 May 1
TI  - New Guidance on Cytochrome P450 2C19 Phenotype-based Use of Proton Pump 
      Inhibitors.
PG  - 697-699
LID - 10.1097/MPG.0000000000003082 [doi]
AB  - Since the approval of the first proton pump inhibitor (PPI) in 1989, our 
      knowledge regarding this class of medications has further developed. An 
      increasing amount of data now supports the association between cytochrome P450 
      2C19 (CYP2C19) phenotype and PPI safety and efficacy. This includes pediatric 
      studies, such as those published here and in other pediatric journals within the 
      past year. Moreover, the most recent pediatric Helicobacter pylori guidelines 
      stated that using the PPIs that are less dependent on CYP2C19 for inactivation 
      may be preferred for H pylori eradication among populations that are more likely 
      to have rapid clearance of CYP2C19-metabolized PPIs. Conversely, pantoprazole 
      package insert recommends a dose reduction in known pediatric CYP2C19 poor 
      metabolizers (PMs), citing a 6-fold increase in serum concentrations compared 
      with normal metabolizers (NMs). The purpose of this communication is to introduce 
      a recently published Clinical Pharmacogenetics Implementation Consortium (CPIC) 
      guideline for CYP2C19 and PPI dosing.
CI  - Copyright (c) 2021 by European Society for Pediatric Gastroenterology, Hepatology, 
      and Nutrition and North American Society for Pediatric Gastroenterology, 
      Hepatology, and Nutrition.
FAU - Sabet, Samie
AU  - Sabet S
AD  - Department of Pediatrics, University of Oklahoma School of Community Medicine, 
      Tulsa, OK.
FAU - McGhee, Jessica E
AU  - McGhee JE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pediatr Gastroenterol Nutr
JT  - Journal of pediatric gastroenterology and nutrition
JID - 8211545
RN  - 0 (Proton Pump Inhibitors)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
SB  - IM
MH  - Child
MH  - Cytochrome P-450 CYP2C19/genetics
MH  - Genotype
MH  - *Helicobacter Infections/drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Phenotype
MH  - Proton Pump Inhibitors
COIS- The authors report no conflicts of interest.
EDAT- 2021/03/16 06:00
MHDA- 2021/07/10 06:00
CRDT- 2021/03/15 13:07
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/07/10 06:00 [medline]
PHST- 2021/03/15 13:07 [entrez]
AID - 00005176-202105000-00013 [pii]
AID - 10.1097/MPG.0000000000003082 [doi]
PST - ppublish
SO  - J Pediatr Gastroenterol Nutr. 2021 May 1;72(5):697-699. doi: 
      10.1097/MPG.0000000000003082.